- Bevacizumab in combination with carboplatin+paclitaxel shows good response and acceptable toxicity.
Why this matters
- The GOG-0240 trial showed efficacy of bevacizumab combined with a cisplatin-paclitaxel or topotecan-paclitaxel doublet in this setting; however, the carboplatin-paclitaxel combination is more widely used in routine practice.
- Phase 2 CECILIA study of 150 patients with recurrent metastatic cervical cancer not amenable to curative surgery and/or radiotherapy received bevacizumab with paclitaxel and carboplatin.
- Funding: F. Hoffmann-La Roche Ltd.
- Median follow-up was 27.8 months.
- Median bevacizumab duration was 6.7 months; 57% of patients received maintenance bevacizumab.
- Disease progression (39%) and adverse events (34%) were the most common reasons for bevacizumab discontinuation.
- Physician’s decision was the most common reason for discontinuing chemotherapy.
- 11.3% of patients experienced ≥1 perforation/fistula event:
- Gastrointestinal perforation/fistula, 4.7%; perforation in 2.0% and fistula in 2.7%.
- Gastrointestinal-vaginal fistula, 4.0%.
- Genitourinary fistula, 4.7%.
- The most common grade 3/4 adverse events were neutropenia (25%), anemia (19%), and hypertension (14%).
- Objective response rate was 61%.
- Median PFS was 10.9 (95% CI, 10.1-13.7) months.
- Median OS was 25.0 (95% CI, 20.9-30.4) months.
- Single group, open label.